Improved Efficacy of Donanemab for Early-stage Alzheimer’s Patients, but Beware of Potential Side Effects

2023-07-17 17:54:00

The new Alzheimer’s drug donanemab seems to work better than previously thought. Patients in the early stages of the disease particularly benefit from it.

However, significant side effects are also possible with the drug from the pharmaceutical company Eli Lilly. In addition to brain swelling, subjects also suffered from cerebral hemorrhage. Three deaths have also been linked to the treatment.

1689619985
#Alzheimers #drug #slows #earlystage #disease

Leave a Replay